Data scientists at the Icahn School of Medicine at Mount Sinai created the model, dubbed “knowledge gap,” to assess the relationship between birth defects, genes and drugs, according to a July 17 press release from Mount Sinai.
Researchers used data produced from the NIH Common Fund programs and datasets from birth defect associations, ReproTox-KG and a semi-supervised learning, to assess approximately 30,000 preclinical small molecule drugs and their potential of crossing the placenta and inducing birth defects.
The analysis found “500 birth-defect/gene/drug cliques,” that could potentially explain molecular mechanisms that could cause drug-induced birth defects.
Researchers warned that the findings are preliminary and that additional research is needed to further validate this.
The full study was published July 17 in Communications Medicine.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
